title: Impaired corpus luteum function and other undesired results of pregnancies associated with inadvertent administration of a long-acting agonist of gonadotrophin-releasing hormone.
abstract: Spontaneous pregnancies associated with inadvertent periconceptional administration of long-acting gonadotrophin releasing-hormone agonist (GnRHa), in in-vitro fertilization, occurred in 11 of 161 patients with non-tubal infertility. All these cases exhibited impaired function of the corpus luteum in terms of declining progesterone levels, despite rising levels of human chorionic gonadotrophin. The patients were categorized according to the timing of GnRHa administration: periovulatory (three cases), midluteal (five cases) and late luteal (three cases). Altogether, of the 11 pregnancies, seven ended with a normal livebirth, three with a preclinical gestation and one with a blighted ovum. It appears that spontaneous pregnancies associated with inadvertent administration of GnRHa are not rare. Awareness for early diagnosis and close hormonal monitoring are recommended for the assessment of corpus luteum function and adequate supplementation.
authors.affiliation: Department of Obstetrics and Gynaecology, Assaf Harofe Medical Centre, Sackler School of Medicine, Tel-Aviv University, Israel.
authors.forename: A
authors.initials: A
authors.lastname: Herman
authors.forename: R
authors.initials: R
authors.lastname: Ron-El
authors.forename: A
authors.initials: A
authors.lastname: Golan
authors.forename: H
authors.initials: H
authors.lastname: Nachum
authors.forename: Y
authors.initials: Y
authors.lastname: Soffer
authors.forename: E
authors.initials: E
authors.lastname: Caspi
mesh_terms: D000328:Adult; D006063:Chorionic Gonadotropin / Q000096:biosynthesis; D003338:Corpus Luteum / Q000187:drug effects* / Q000502:physiology; D015536:Down-Regulation; D004958:Estradiol / Q000627:therapeutic use; D005260:Female; D005307:Fertilization in Vitro / Q000379:methods; D007987:Gonadotropin-Releasing Hormone / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D006801:Humans; D008183:Luteal Phase; D007986:Luteinizing Hormone / Q000097:blood; D008186:Luteolytic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D007752:Obstetric Labor, Premature / Q000188:drug therapy; D011247:Pregnancy; D011256:Pregnancy Outcome; D011374:Progesterone / Q000096:biosynthesis / Q000627:therapeutic use; D011966:Receptors, LHRH / Q000187:drug effects*; D017329:Triptorelin Pamoate
chemical_list: D006063:Chorionic Gonadotropin; D008186:Luteolytic Agents; D011966:Receptors, LHRH; D017329:Triptorelin Pamoate; D007987:Gonadotropin-Releasing Hormone; D011374:Progesterone; D004958:Estradiol; D007986:Luteinizing Hormone